-
FDA approves Praluent to reduce risk of heart attacks, strokes and heart pain requiring hospitalization
Time of Update: 2020-06-09
high levels of LDL-C in the blood, also known as "bad" cholesterol, can increase the risk of severe cardiovascular events in patients Adults who have had a heart attack or stroke are at a one-third
-
Amgen's new RANKL inhibitor, ground-shoian-resistant injection, has been approved by the State Drug Administration
Time of Update: 2020-06-09
osteoblastoma is an extremely rare and rapidly advanced, high-risk primary bone tumor rich in human nuclear factor activation factor receptor ligand (RANKL), which manifests itself as eccentric oste
-
NMPA approves New Anti-Cancer Drug Halaven for Use in Patients With LocalIzed Advanced or Metastatic Breast Cancer
Time of Update: 2020-06-09
today, The Regulatory Authority (NMPA) of China's Medicines (http:// has approved its in-house development of the new anti-cancer drug Halaven (eribulin mesylin, ereblin), for localized or metast
-
FDA approves Revlimid and rituxima combination therapy for the treatment of adults with flistic lymphoma or marginal lymphoma
Time of Update: 2020-06-09
recently, the United States FDA (http:// has approved Revlimid (Linamine) and rituximab combination therapy (R2) for adult stoic patients with previously treated flicosive lymphoma (FL) or margin
-
FDA approves Pfizer Vyndaqel and Vyndamax for treatment of myocardial disease caused by amyloid degeneration
Time of Update: 2020-06-09
AATR-CM is a rare, life-threatening disease It is caused by the instability of the TTR TTR usually exists in the form of tetrapolymers, which, when unstable tetrapolymers are dissofarted, cause setr
-
FDA approves Takeda Gattex for treatment of children with short bowel syndrome over 1 year of age
Time of Update: 2020-06-09
In children, SBS is a chronic, life-threatening disease Patients due to congenital or acquired disease, need surgery to remove most of the intestines, resulting in poor absorption of nutrients and m
-
AstraZeneca PARP inhibitor Lynparza (olaparib) approved by the European Commission
Time of Update: 2020-06-09
yesterday (June 18), AstraZeneca announced that its PARP inhibitor Lynparza (olaparib) has been approved by the European Commission as a first-line maintenance therapy for patients with advanced ova
-
FDA approves Lilly Cyramza as monotherapy for hepatocellular cancer patients
Time of Update: 2020-06-09
recently, The FDA's (http:// announced the approval of Eli Lilly's company, , http:// , as a single-drug treatment for patients with hepatocellular carcinoma (HCC) These patients have been treat
-
Intec's innovative flu treatment Xofluza (baloxavir marboxil) reaches major end in Phase 3 clinical trial
Time of Update: 2020-06-09
Today, Roche's Genetech company, (http:// , announced that its innovative flu treatment, Baloxavir marboxil, had reached its main point in the global phase 3 clinical trial (http:// called MINI
-
Nanjing Zhengda Tianqing 3 generic drug "Tegrelo" officially approved by the State Drug Administration (NMPA) for listing
Time of Update: 2020-06-09
yesterday (July 1), Nanjing Zhengda Tianqing 3 imitation Pharmaceutical (http:// "Tegrelo" was officially approved by the State Drug Administration (NMPA) for listing, becoming the third approved
-
Seltorexant (MIN-202) reaches primary and critical secondary endpoint in Phase 2b clinical trials for insomnia patients
Time of Update: 2020-06-09
today, Minerva company (http:// announced that the company's joint development with Janssen,""min-202" reached the primary and critical secondary endpoint sydd of the trial in the phase 2b clinic
-
Lilly releases post-mortem data for the migraine drug Emgality Phase III clinical program
Time of Update: 2020-06-09
migraine is the second most disabled cause in the United States and can seriously affect the lives of patients Emgality treatment can effectively reduce the number of days of migraine attacks per mo
-
FDA approves Ruzurgi pill to treat Lambert-Eaton muscle weakness syndrome at age 6-17
Time of Update: 2020-06-09
LEMS is a rare autoimmune disease that affects the connection between nerves and muscles, leading to muscle weakness and other symptoms LemS patients with their own immune systems attack neuromuscul
-
FDA approves aplastic Eylea (aflibercept) to treat all stages of diabetic retinopathy
Time of Update: 2020-06-09
today, the u.S FDA (http:// approved the company's Eylea (dr) for the treatment of diabetic dysleuretic lesions at all stages to reduce a patient's risk of blindness, http:// announced today Ab
-
GSK new ICS/LABA drug Wanruishu ® officially enter the Chinese market
Time of Update: 2020-06-09
recently, GSK China announced that its new ICS/LABA Drug (http:// Wanruishu ® (generic name: fluoroteason/Verantro, FF/VI) has officially entered the Chinese market as the only once-a-day ICS/LA
-
The forgreotablets (90mg) developed by Stone Pharmaceutical Group have been approved by the State Drug Administration for registration of drugs
Time of Update: 2020-06-09
recently, Stone Pharmaceutical Group announced that its affiliated company (http:// stone pharmaceutical group, O'Italian Pharmaceutical Co., Ltd developed for the Grelo tablets (90mg) has been i
-
Anjin Angarvi ® (Tsu-mono-injection) approved by the State Drug Administration
Time of Update: 2020-06-09
osteoblastoma is a histologically benign, but often invasive bone tumor, which occurs in the young and middle age population between the ages of 20 and 40, and the incidence of female sons is slight
-
Mercado's heavy immunotherapy Keytruda wins two new adaptations
Time of Update: 2020-06-09
today, MsSD announced that its heavy immunotherapy Keytruda has won two new indications Keytruda has been approved by the U.S FDA (http:// as a single-line treatment for patients with advanced h
-
Poxel announces positive top line data for a PK/PD clinical study of the new oral anti-sugar drug imeglimin
Time of Update: 2020-06-09
recently, france's Poxel company (http:// and partner me tavant Sciences jointly announced the positive top line data for a PK/PD clinical study of the new oral sugar-reducing drug imeglimin The
-
Zealand Pharma's peptide-based therapy dasiglucagon Phase 3 clinical trial reaches primary and secondary end points of trial
Time of Update: 2020-06-09
today, The http:// of The Peptide-based Therapy developed by The Company has reached the primary end and all critical secondary endpoints in the validation of the Phase 3 Clinical Trial (http://
